Trials / Terminated
TerminatedNCT04586920
A Study of LY3509754 in Healthy Non-Japanese and Japanese Participants
A Phase 1, Randomized, Participant-and Investigator-Blind, Placebo-Controlled, Single-and Multiple-Ascending Dose, Drug-Drug Interaction and Food Effect Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3509754 in Healthy Non-Japanese and Japanese Participants
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 104 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study in healthy participants is to learn more about the safety of LY3509754 and any side effects that might be associated with it. Blood tests will be performed to check how much LY3509754 gets into the bloodstream and how long it takes the body to eliminate it.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3509754 | Administered orally |
| DRUG | Placebo | Administered orally |
| DRUG | Itraconazole | Administered orally |
| DRUG | Midazolam | Administered orally |
Timeline
- Start date
- 2020-10-20
- Primary completion
- 2022-10-14
- Completion
- 2022-10-14
- First posted
- 2020-10-14
- Last updated
- 2025-01-03
- Results posted
- 2025-01-03
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04586920. Inclusion in this directory is not an endorsement.